Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration.
allergy treament
atopic dermatitis
barrier
environment
hygiene hypothesis
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
04 Aug 2024
04 Aug 2024
Historique:
revised:
18
06
2024
received:
09
02
2024
accepted:
04
07
2024
medline:
5
8
2024
pubmed:
5
8
2024
entrez:
5
8
2024
Statut:
aheadofprint
Résumé
The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together top leaders from research, clinical practice, policy, and patient advocacy to discuss the critical aspects of AD, including neuroimmunology, environmental factors, comorbidities, and breakthroughs in prevention, diagnosis, and treatment. The discussions were geared towards fostering a collaborative approach to integrate these advancements into practical, patient-centric care. The forum underlined the mounting burden of AD, attributing it to significant environmental and lifestyle changes. It acknowledged the progress in understanding AD and in developing targeted therapies but recognized a gap in translating these innovations into clinical practice. Emphasis was placed on the need for enhanced awareness, education, and stakeholder engagement to address this gap effectively and to consider environmental and lifestyle factors in a comprehensive disease management strategy. The 4th Davos Declaration marks a significant milestone in the journey to improve care for people with AD. By promoting a holistic approach that combines research, education, and clinical application, the Forum sets a roadmap for stakeholders to collaborate to improve patient outcomes in AD, reflecting a commitment to adapt and respond to the dynamic challenges of AD in a changing world.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Author(s). Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
Ring J, Akdis C, Behrendt H, et al. Davos declaration: allergy as a global problem. Allergy. 2012;67(2):141‐143. doi:10.1111/j.1398-9995.2011.02770.x
Ring J, Akdis C, Lauener R, Schäppi G, et al. Global allergy forum and second Davos declaration 2013 allergy: barriers to cure—challenges and actions to be taken. Allergy. 2014;69(8):978‐982. doi:10.1111/all.12406
Bieber T, Akdis C, Lauener R, Traidl‐Hoffmann C, et al. Global allergy forum and 3rd Davos declaration 2015: atopic dermatitis/eczema: challenges and opportunities toward precision medicine. Allergy. 2016;71(5):588‐592. doi:10.1111/all.12857
Elezbawy B, Fasseeh AN, Fouly E, Tannira M, et al. Humanistic and economic burden of atopic dermatitis for adults and adolescents in the Middle East and Africa region. Dermatol Ther. 2023;13(1):131‐146. doi:10.1007/s13555-022-00857-0
Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21‐40. doi:10.1038/s41573-021-00266-6
Geba GP, Li D, Xu M, et al. Attenuating the atopic march: meta‐analysis of the dupilumab atopic dermatitis database for incident allergic events. J Allergy Clin Immunol. 2023;151(3):756‐766. doi:10.1016/j.jaci.2022.08.026
Lunjani N, Ambikan AT, Hlela C, et al. Rural and urban exposures shape early life immune development in south African children with atopic dermatitis and nonallergic children. Allergy. 2023;79:65‐79. doi:10.1111/all.15832
Pawankar R, Akdis CA. Climate change and the epithelial barrier theory in allergic diseases: a one health approach to a green environment. Allergy. 2023;78(11):2829‐2834. doi:10.1111/all.15885
Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22(8):662‐680. doi:10.1038/s41573-023-00735-0
Mitamura Y, Ogulur I, Pat Y, et al. Dysregulation of the epithelial barrier by environmental and other exogenous factors. Contact Derm. 2021;85(6):615‐626. doi:10.1111/cod.13959
Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Epithelial barrier hypothesis: effect of the external exposome on the microbiome and epithelial barriers in allergic disease. Allergy. 2022;77(5):1418‐1449. doi:10.1111/all.15240
Trautmann A, Akdis M, Kleemann D, et al. T cell‐mediated Fas‐induced keratinocyte apoptosis plays a key pathogenetic role in eczematous dermatitis. J Clin Invest. 2000;106(1):25‐35. doi:10.1172/JCI9199
Stefanovic N, Irvine AD. Filaggrin and beyond: new insights into the skin barrier in atopic dermatitis and allergic diseases, from genetics to therapeutic perspectives. Ann Allergy Asthma Immunol. 2023;132:187‐195. doi:10.1016/j.anai.2023.09.009
McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. J Allergy Clin Immunol. 2013;131(2):280‐291. doi:10.1016/j.jaci.2012.12.668
Akdis CA. Does the epithelial barrier hypothesis explain the increase in allergy, autoimmunity and other chronic conditions? Nat Rev Immunol. 2021;21(11):739‐751. doi:10.1038/s41577-021-00538-7
Xian M, Wawrzyniak P, Rückert B, et al. Anionic surfactants and commercial detergents decrease tight junction barrier integrity in human keratinocytes. J Allergy Clin Immunol. 2016;138(3):890‐893.e9. doi:10.1016/j.jaci.2016.07.003
Tanzer J, Meng D, Ohsaki A, et al. Laundry detergent promotes allergic skin inflammation and esophageal eosinophilia in mice. PLoS One. 2022;17(6):e0268651. doi:10.1371/journal.pone.0268651
Rinnov MR, Halling AS, Gerner T, et al. Skin biomarkers predict development of atopic dermatitis in infancy. Allergy. 2023;78(3):791‐802. doi:10.1111/all.15518
Halling AS, Bager P, Skov L, et al. The interaction between filaggrin mutations and hard domestic water and the risk of early‐onset atopic dermatitis. Br J Dermatol. 2020;183(2):406‐407. doi:10.1111/bjd.18965
Renert‐Yuval Y, Del Duca E, Pavel AB, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148(1):148‐163. doi:10.1016/j.jaci.2021.01.001
Pavel AB, Renert‐Yuval Y, Wu J, et al. Tape strips from early‐onset pediatric atopic dermatitis highlight disease abnormalities in nonlesional skin. Allergy. 2021;76(1):314‐325. doi:10.1111/all.14490
Kortekaas Krohn I, Aerts JL, Breckpot K, et al. T‐cell subsets in the skin and their role in inflammatory skin disorders. Allergy. 2022;77(3):827‐842. doi:10.1111/all.15104
Howell MD, Kim BE, Gao P, et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol. 2009;124(3 Suppl 2):R7‐R12. doi:10.1016/j.jaci.2009.07.012
Bieber T. Interleukin‐13: targeting an underestimated cytokine in atopic dermatitis. Allergy. 2020;75(1):54‐62. doi:10.1111/all.13954
Tollenaere MAX, Litman T, Moebus L, et al. Skin barrier and inflammation genes associated with atopic dermatitis are regulated by interleukin‐13 and modulated by tralokinumab in vitro. Acta Derm Venereol. 2021;101(4):adv00447. doi:10.2340/00015555-3810
Ständer S, Yosipovitch G, Legat FJ, et al. Trial of nemolizumab in moderate‐to‐severe prurigo nodularis. N Engl J Med. 2020;382(8):706‐716. doi:10.1056/NEJMoa1908316
Beck LA, Thaçi D, Hamilton JD, et al. Dupilumab treatment in adults with moderate‐to‐severe atopic dermatitis. N Engl J Med. 2014;371(2):130‐139. doi:10.1056/NEJMoa1314768
Berdyshev E, Goleva E, Bissonnette R, et al. Dupilumab significantly improves skin barrier function in patients with moderate‐to‐severe atopic dermatitis. Allergy. 2022;77(11):3388‐3397. doi:10.1111/all.15432
Beck LA, Bieber T, Weidinger S, et al. Tralokinumab treatment improves the skin microbiota by increasing the microbial diversity in adults with moderate‐to‐severe atopic dermatitis: analysis of microbial diversity in ECZTRA 1, a randomized controlled trial. J Am Acad Dermatol. 2023;88(4):816‐823. doi:10.1016/j.jaad.2022.11.047
Rohner MH, Thormann K, Cazzaniga S, et al. Dupilumab reduces inflammation and restores the skin barrier in patients with atopic dermatitis. Allergy. 2021;76(4):1268‐1270. doi:10.1111/all.14664
Brough HA, Lanser BJ, Sindher SB, et al. Early intervention and prevention of allergic diseases. Allergy. 2022;77(2):416‐441. doi:10.1111/all.15006
Sindher SB, Long A, Chin AR, et al. Food allergy, mechanisms, diagnosis and treatment: innovation through a multi‐targeted approach. Allergy. 2022;77(10):2937‐2948. doi:10.1111/all.15418
Bangert C, Rindler K, Krausgruber T, et al. Persistence of mature dendritic cells, TH2A, and Tc2 cells characterize clinically resolved atopic dermatitis under IL‐4Rα blockade. Sci Immunol. 2021;6(55):eabe2749. doi:10.1126/sciimmunol.abe2749
Zhang B, Roesner LM, Traidl S, et al. Single‐cell profiles reveal distinctive immune response in atopic dermatitis in contrast to psoriasis. Allergy. 2023;78(2):439‐453. doi:10.1111/all.15486
Naik S, Larsen SB, Gomez NC, et al. Inflammatory memory sensitizes skin epithelial stem cells to tissue damage. Nature. 2017;550(7677):475‐480. doi:10.1038/nature24271
Alkon N, Bauer W, Krausgruber T, et al. Single‐cell analysis reveals innate lymphoid cell lineage infidelity in atopic dermatitis. J Allergy Clin Immunol. 2022;149(2):624‐639. doi:10.1016/j.jaci.2021.07.025
Naik S, Fuchs E. Inflammatory memory and tissue adaptation in sickness and in health. Nature. 2022;607(7918):249‐255. doi:10.1038/s41586-022-04919-3
Gläser R, Harder J, Lange H, Bartels J, Christophers E, Schröder JM. Antimicrobial psoriasin (S100A7) protects human skin from Escherichia coli infection. Nat Immunol. 2005;6(1):57‐64. doi:10.1038/ni1142
Murdoch CC, Skaar EP. Nutritional immunity: the battle for nutrient metals at the host‐pathogen interface. Nat Rev Microbiol. 2022;20(11):657‐670. doi:10.1038/s41579-022-00745-6
Ong PY, Ohtake T, Brandt C, et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med. 2002;347(15):1151‐1160. doi:10.1056/NEJMoa021481
Harder J, Dressel S, Wittersheim M, et al. Enhanced expression and secretion of antimicrobial peptides in atopic dermatitis and after superficial skin injury. J Invest Dermatol. 2010;130(5):1355‐1364. doi:10.1038/jid.2009.432
Traidl S, Roesner L, Zeitvogel J, Werfel T. Eczema herpeticum in atopic dermatitis. Allergy. 2021;76(10):3017‐3027. doi:10.1111/all.14853
Hata TR, Kotol P, Boguniewicz M, et al. History of eczema herpeticum is associated with the inability to induce human β‐defensin (HBD)‐2, HBD‐3 and cathelicidin in the skin of patients with atopic dermatitis. Br J Dermatol. 2010;163(3):659‐661. doi:10.1111/j.1365-2133.2010.09892.x
Latendorf T, Gerstel U, Wu Z, et al. Cationic intrinsically disordered antimicrobial peptides (CIDAMPs) represent a new paradigm of innate defense with a potential for novel anti‐infectives. Sci Rep. 2019;9(1):3331. doi:10.1038/s41598-019-39219-w
Niehues H, Tsoi LC, van der Krieken DA, et al. Psoriasis‐associated late cornified envelope (LCE) proteins have antibacterial activity. J Invest Dermatol. 2017;137(11):2380‐2388. doi:10.1016/j.jid.2017.06.003
Gerstel U, Latendorf T, Bartels J, Becker A, Tholey A, Schröder JM. Hornerin contains a linked series of ribosome‐targeting peptide antibiotics. Sci Rep. 2018;8(1):16158. doi:10.1038/s41598-018-34467-8
Deng L, Costa F, Blake KJ, et al. S. aureus drives itch and scratch‐induced skin damage through a V8 protease‐PAR1 axis. Cell. 2023;186(24):5375‐5393.e25. doi:10.1016/j.cell.2023.10.019
Shelley JR, McHugh BJ, Wills J, et al. A mechanistic evaluation of human beta defensin 2 mediated protection of human skin barrier in vitro. Sci Rep. 2023;13(1):2271. doi:10.1038/s41598-023-29558-0
Man K, Kutyavin VI, Chawla A. Tissue immunometabolism: development, physiology, and pathobiology. Cell Metab. 2017;25(1):11‐26. doi:10.1016/j.cmet.2016.08.016
Afghani J, Traidl‐Hoffmann C, Schmitt‐Kopplin P, Reiger M, Mueller C. An overview of the latest metabolomics studies on atopic eczema with new directions for study. Int J Mol Sci. 2022;23(15):8791. doi:10.3390/ijms23158791
Ottas A, Fishman D, Okas TL, et al. Blood serum metabolome of atopic dermatitis: altered energy cycle and the markers of systemic inflammation. PLoS One. 2017;12(11):e0188580. doi:10.1371/journal.pone.0188580
Martínez BA, Shrotri S, Kingsmore KM, Bachali P, Grammer AC, Lipsky PE. Machine learning reveals distinct gene signature profiles in lesional and nonlesional regions of inflammatory skin diseases. Sci Adv. 2022;8(17):eabn4776. doi:10.1126/sciadv.abn4776
Yin H, Qiu Z, Zhu R, et al. Dysregulated lipidome of sebum in patients with atopic dermatitis. Allergy. 2023;78(6):1524‐1537. doi:10.1111/all.15569
Zhang L, Wen X, Hou Y, et al. Integrated metabolomics and lipidomics study of patients with atopic dermatitis in response to dupilumab. Front Immunol. 2022;13:1002536. doi:10.3389/fimmu.2022.1002536
Trompette A, Pernot J, Perdijk O, et al. Gut‐derived short‐chain fatty acids modulate skin barrier integrity by promoting keratinocyte metabolism and differentiation. Mucosal Immunol. 2022;15(5):908‐926. doi:10.1038/s41385-022-00524-9
Steinhoff M, Ahmad F, Pandey A, et al. Neuroimmune communication regulating pruritus in atopic dermatitis. J Allergy Clin Immunol. 2022;149(6):1875‐1898. doi:10.1016/j.jaci.2022.03.010
Oetjen LK, Mack MR, Feng J, et al. Sensory neurons co‐opt classical immune signaling pathways to mediate chronic itch. Cell. 2017;171(1):217‐228.e13. doi:10.1016/j.cell.2017.08.006
Trier AM, Mack MR, Fredman A, et al. IL‐33 signaling in sensory neurons promotes dry skin itch. J Allergy Clin Immunol. 2022;149(4):1473‐1480.e6. doi:10.1016/j.jaci.2021.09.014
Keren A, Reich K, Bertolini M, et al. Autologous Th2‐polarized lymphocytes induce atopic dermatitis lesions in non‐atopic human skin xenotransplants. Allergy. 2023;78(6):1538‐1553. doi:10.1111/all.15635
Stefanovic N, Irvine AD, Flohr C. The role of the environment and exposome in atopic dermatitis. Curr Treat Options Allergy. 2021;8(3):222‐241. doi:10.1007/s40521-021-00289-9
Wang SP, Stefanovic N, Orfali RL, et al. Impact of climate change on atopic dermatitis: a review by the international eczema council. Allergy. 2024;79:1455‐1469. doi:10.1111/all.16007
Pfaar O, Klimek L, Jutel M, Akdis CA, et al. COVID‐19 pandemic: practical considerations on the organization of an allergy clinic‐an EAACI/ARIA position paper. Allergy. 2021;76(3):648‐676. doi:10.1111/all.14453
Fadadu RP, Green M, Jewell NP, Grimes B, Vargo J, Wei ML. Association of exposure to wildfire air pollution with exacerbations of atopic dermatitis and itch among older adults. JAMA Netw Open. 2022;5(10):e2238594. doi:10.1001/jamanetworkopen.2022.38594
Donald K, Finlay BB. Early‐life interactions between the microbiota and immune system: impact on immune system development and atopic disease. Nat Rev Immunol. 2023;23(11):735‐748. doi:10.1038/s41577-023-00874-w
Agache I, Sampath V, Aguilera J, et al. Climate change and global health: a call to more research and more action. Allergy. 2022;77(5):1389‐1407. doi:10.1111/all.15229
Perera F, Nadeau K. Climate change, fossil‐fuel pollution, and children's health. N Engl J Med. 2022;386(24):2303‐2314. doi:10.1056/NEJMra2117706
Kiewiet MBG, Grundström J, Apostolovic D, et al. Elucidating the α‐gal syndrome at the molecular allergen level. Allergy. 2021;76(5):1576‐1578. doi:10.1111/all.14660
Apostolovic D, Mihailovic J, Commins SP, et al. Allergenomics of the tick Ixodes ricinus reveals important α‐gal‐carrying IgE‐binding proteins in red meat allergy. Allergy. 2020;75(1):217‐220. doi:10.1111/all.13978
Apostolovic D, Tran TAT, Hamsten C, Starkhammar M, Cirkovic Velickovic T, van Hage M. Immunoproteomics of processed beef proteins reveal novel galactose‐α‐1,3‐galactose‐containing allergens. Allergy. 2014;69(10):1308‐1315. doi:10.1111/all.12462
Perusko M, Apostolovic D, Kiewiet MBG, et al. Bovine γ‐globulin, lactoferrin, and lactoperoxidase are relevant bovine milk allergens in patients with α‐gal syndrome. Allergy. 2021;76(12):3766‐3775. doi:10.1111/all.14889
Effner R, Hiller J, Eyerich S, et al. Cytochrome P450s in human immune cells regulate IL‐22 and c‐kit via an AHR feedback loop. Sci Rep. 2017;7:44005. doi:10.1038/srep44005
Zhao F, Elkelish A, Durner J, et al. Common ragweed (Ambrosia artemisiifolia L.): allergenicity and molecular characterization of pollen after plant exposure to elevated NO2. Plant Cell Environ. 2016;39(1):147‐164. doi:10.1111/pce.12601
Oeder S, Alessandrini F, Wirz OF, et al. Pollen‐derived nonallergenic substances enhance Th2‐induced IgE production in B cells. Allergy. 2015;70(11):1450‐1460. doi:10.1111/all.12707
El Kelish A, Zhao F, Heller W, et al. Ragweed (Ambrosia artemisiifolia) pollen allergenicity: SuperSAGE transcriptomic analysis upon elevated CO2 and drought stress. BMC Plant Biol. 2014;14:176. doi:10.1186/1471-2229-14-176
Beck I, Jochner S, Gilles S, et al. High environmental ozone levels lead to enhanced allergenicity of birch pollen. PLoS One. 2013;8(11):e80147. doi:10.1371/journal.pone.0080147
Ege MJ, Mayer M, Normand AC, et al. Exposure to environmental microorganisms and childhood asthma. N Engl J Med. 2011;364(8):701‐709. doi:10.1056/NEJMoa1007302
Jensen SA, Fiocchi A, Baars T, et al. Diagnosis and rationale for action against cow's milk allergy (DRACMA) guidelines update–III–cow's milk allergens and mechanisms triggering immune activation. World Allergy Organ J. 2022;15(9):100668. doi:10.1016/j.waojou.2022.100668
Deckers J, Lambrecht BN, Hammad H. How a farming environment protects from atopy. Curr Opin Immunol. 2019;60:163‐169. doi:10.1016/j.coi.2019.08.001
Bartosik T, Jensen SA, Afify SM, et al. Ameliorating atopy by compensating micronutritional deficiencies in immune cells: a double‐blind placebo‐controlled pilot study. J Allergy Clin Immunol Pract. 2022;10(7):1889‐1902.e9. doi:10.1016/j.jaip.2022.02.028
Bigliardi PL. Role of skin pH in psoriasis. Curr Probl Dermatol. 2018;54:108‐114. doi:10.1159/000489524
Hülpüsch C, Tremmel K, Hammel G, et al. Skin pH–dependent Staphylococcus aureus abundance as predictor for increasing atopic dermatitis severity. Allergy. 2020;75(11):2888‐2898. doi:10.1111/all.14461
Paller AS, Kong HH, Seed P, et al. The microbiome in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):26‐35. doi:10.1016/j.jaci.2018.11.015
Halling AS, Fritz BG, Gerner T, et al. Reduced skin microbiome diversity in infancy is associated with increased risk of atopic dermatitis in high‐risk children. J Invest Dermatol. 2023;143(10):2030‐2038.e6. doi:10.1016/j.jid.2023.03.1682
Georgountzou A, Papadopoulos NG. Postnatal innate immune development: from birth to adulthood. Front Immunol. 2017;8:957. doi:10.3389/fimmu.2017.00957
Halling AS, Rinnov MR, Ruge IF, et al. Skin TARC/CCL17 increase precedes the development of childhood atopic dermatitis. J Allergy Clin Immunol. 2023;151(6):1550‐1557.e6. doi:10.1016/j.jaci.2022.11.023
Kawamoto N, Kaneko H, Takemura M, et al. Age‐related changes in intracellular cytokine profiles and Th2 dominance in allergic children. Pediatr Allergy Immunol. 2006;17(2):125‐133. doi:10.1111/j.1399-3038.2005.00363.x
Wang S, Zhu R, Gu C, et al. Distinct clinical features and serum cytokine pattern of elderly atopic dermatitis in China. J Eur Acad Dermatol Venereol. 2020;34(10):2346‐2352. doi:10.1111/jdv.16346
Thyssen JP, Halling AS, Schmid‐Grendelmeier P, Guttman‐Yassky E, Silverberg JI. Comorbidities of atopic dermatitis‐what does the evidence say? J Allergy Clin Immunol. 2023;151(5):1155‐1162. doi:10.1016/j.jaci.2022.12.002
Tham EH, Rajakulendran M, Lee BW, Van Bever HPS. Epicutaneous sensitization to food allergens in atopic dermatitis: what do we know? Pediatr Allergy Immunol. 2020;31(1):7‐18. doi:10.1111/pai.13127
Wollenberg A, Thomsen SF, Lacour JP, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence. World Allergy Organ J. 2021;14(3):100519. doi:10.1016/j.waojou.2021.100519
Abuabara K, Ye M, McCulloch CE, et al. Clinical onset of atopic eczema: results from 2 nationally representative British birth cohorts followed through midlife. J Allergy Clin Immunol. 2019;144(3):710‐719. doi:10.1016/j.jaci.2019.05.040
Maintz L, Schmitz MT, Herrmann N, et al. Atopic dermatitis: correlation of distinct risk factors with age of onset in adulthood compared to childhood. Allergy. 2023;78(8):2181‐2201. doi:10.1111/all.15721
Kim D, Kobayashi T, Nagao K. Research techniques made simple: mouse models of atopic dermatitis. J Invest Dermatol. 2019;139(5):984‐990.e1. doi:10.1016/j.jid.2019.02.014
Jin H, He R, Oyoshi M, Geha RS. Animal models of atopic dermatitis. J Invest Dermatol. 2009;129(1):31‐40. doi:10.1038/jid.2008.106
Marsella R. Atopic dermatitis in domestic animals: what our current understanding is and how this applies to clinical practice. Vet Sci. 2021;8(7):124. doi:10.3390/vetsci8070124
Maintz L, Welchowski T, Herrmann N, et al. Machine learning‐based deep phenotyping of atopic dermatitis: severity‐associated factors in adolescent and adult patients. JAMA Dermatol. 2021;157(12):1414‐1424. doi:10.1001/jamadermatol.2021.3668
Tan KJ, Nakamizo S, Lee‐Okada HC, et al. A Western diet alters skin ceramides and compromises the skin barrier in ears. J Invest Dermatol. 2022;142(7):2020‐2023.e2. doi:10.1016/j.jid.2021.12.017
Venter C, Palumbo MP, Sauder KA, et al. Associations between child filaggrin mutations and maternal diet with the development of allergic diseases in children. Pediatr Allergy Immunol. 2022;33(3):e13753. doi:10.1111/pai.13753
Venter C, Greenhawt M, Meyer RW, et al. EAACI position paper on diet diversity in pregnancy, infancy and childhood: novel concepts and implications for studies in allergy and asthma. Allergy. 2020;75(3):497‐523. doi:10.1111/all.14051
Jafferany M, Davari ME. Itch and psyche: psychiatric aspects of pruritus. Int J Dermatol. 2019;58(1):3‐23. doi:10.1111/ijd.14081
Grundmann S, Ständer S. Chronic pruritus: clinics and treatment. Ann Dermatol. 2011;23(1):1‐11. doi:10.5021/ad.2011.23.1.1
Darsow U, Drzezga A, Frisch M, et al. Processing of histamine‐induced itch in the human cerebral cortex: a correlation analysis with dermal reactions. J Invest Dermatol. 2000;115(6):1029‐1033. doi:10.1046/j.1523-1747.2000.00193.x
Trier AM, Mack MR, Kim BS. The neuroimmune axis in skin sensation, inflammation, and immunity. J Immunol. 2019;202(10):2829‐2835. doi:10.4049/jimmunol.1801473
Ekblom A, Lundeberg T, Wahlgren CF. Influence of calcitonin gene‐related peptide on histamine‐ and substance P‐induced itch, flare and weal in humans. Skin Pharmacol. 1993;6(3):215‐222. doi:10.1159/000211138
Eftekhari S, Warfvinge K, Blixt FW, Edvinsson L. Differentiation of nerve fibers storing CGRP and CGRP receptors in the peripheral trigeminovascular system. J Pain. 2013;14(11):1289‐1303. doi:10.1016/j.jpain.2013.03.010
Steinhoff M, Buddenkotte J, Lerner EA. Role of mast cells and basophils in pruritus. Immunol Rev. 2018;282(1):248‐264. doi:10.1111/imr.12635
Graham HT, Lowry OH, Wahl N, Priebat MK. Mast cells as sources of tissue histamine. J Exp Med. 1955;102(3):307‐318. doi:10.1084/jem.102.3.307
Malaviya R, Morrison AR, Pentland AP. Histamine in human epidermal cells is induced by ultraviolet light injury. J Invest Dermatol. 1996;106(4):785‐789. doi:10.1111/1523-1747.ep12346356
Wang F, Yang TLB, Kim BS. The return of the mast cell: new roles in neuroimmune itch biology. J Invest Dermatol. 2020;140(5):945‐951. doi:10.1016/j.jid.2019.12.011
Wang F, Trier AM, Li F, et al. A basophil‐neuronal axis promotes itch. Cell. 2021;184(2):422‐440.e17. doi:10.1016/j.cell.2020.12.033
Kaur G, Singh N, Jaggi AS. Mast cells in neuropathic pain: an increasing spectrum of their involvement in pathophysiology. Rev Neurosci. 2017;28(7):759‐766. doi:10.1515/revneuro-2017-0007
Kushnir‐Sukhov NM, Brown JM, Wu Y, Kirshenbaum A, Metcalfe DD. Human mast cells are capable of serotonin synthesis and release. J Allergy Clin Immunol. 2007;119(2):498‐499. doi:10.1016/j.jaci.2006.09.003
Toru H, Pawankar R, Ra C, Yata J, Nakahata T. Human mast cells produce IL‐13 by high‐affinity IgE receptor cross‐linking: enhanced IL‐13 production by IL‐4‐primed human mast cells. J Allergy Clin Immunol. 1998;102(3):491‐502. doi:10.1016/s0091-6749(98)70140-x
Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med. 1992;176(5):1381‐1386. doi:10.1084/jem.176.5.1381
Burd PR, Thompson WC, Max EE, Mills FC. Activated mast cells produce interleukin 13. J Exp Med. 1995;181(4):1373‐1380. doi:10.1084/jem.181.4.1373
Furue M, Yamamura K, Kido‐Nakahara M, Nakahara T, Fukui Y. Emerging role of interleukin‐31 and interleukin‐31 receptor in pruritus in atopic dermatitis. Allergy. 2018;73(1):29‐36. doi:10.1111/all.13239
Wilson SR, Thé L, Batia LM, et al. The epithelial cell‐derived atopic dermatitis cytokine TSLP activates neurons to induce itch. Cell. 2013;155(2):285‐295. doi:10.1016/j.cell.2013.08.057
Ständer S, Gunzer M, Metze D, Luger T, Steinhoff M. Localization of mu‐opioid receptor 1A on sensory nerve fibers in human skin. Regul Pept. 2002;110(1):75‐83. doi:10.1016/s0167-0115(02)00159-3
Pfab F, Kirchner MT, Huss‐Marp J, et al. Acupuncture compared with oral antihistamine for type I hypersensitivity itch and skin response in adults with atopic dermatitis: a patient‐ and examiner‐blinded, randomized, placebo‐controlled, crossover trial. Allergy. 2012;67(4):566‐573. doi:10.1111/j.1398-9995.2012.02789.x
Stumpf A, Zerey V, Heuft G, Ständer S, Pfleiderer B, Schneider G. Itch perception and skin reactions as modulated by verbal suggestions: role of participant's and investigator's sex. Acta Derm Venereol. 2016;96(5):619‐623. doi:10.2340/00015555-2336
Bartels DJP, van Laarhoven AIM, Stroo M, et al. Minimizing nocebo effects by conditioning with verbal suggestion: a randomized clinical trial in healthy humans. PLoS One. 2017;12(9):e0182959. doi:10.1371/journal.pone.0182959
Stumpf A, Schneider G, Ständer S. Psychosomatic and psychiatric disorders and psychologic factors in pruritus. Clin Dermatol. 2018;36(6):704‐708. doi:10.1016/j.clindermatol.2018.08.015
Dalgard FJ, Gieler U, Tomas‐Aragones L, et al. The psychological burden of skin diseases: a cross‐sectional multicenter study among dermatological out‐patients in 13 European countries. J Invest Dermatol. 2015;135(4):984‐991. doi:10.1038/jid.2014.530
Dieris‐Hirche J, Gieler U, Kupfer JP, Milch WE. Suicidal ideation, anxiety and depression in adult patients with atopic dermatitis. Hautarzt. 2009;60(8):641‐646. doi:10.1007/s00105-009-1744-y
Roesner LM, Farag AK, Pospich R, Traidl S, Werfel T. T‐cell receptor sequencing specifies psoriasis as a systemic and atopic dermatitis as a skin‐focused, allergen‐driven disease. Allergy. 2022;77(9):2737‐2747. doi:10.1111/all.15272
Ascott A, Mulick A, Yu AM, et al. Atopic eczema and major cardiovascular outcomes: a systematic review and meta‐analysis of population‐based studies. J Allergy Clin Immunol. 2019;143(5):1821‐1829. doi:10.1016/j.jaci.2018.11.030
Thyssen JP, Halling‐Overgaard AS, Andersen YMF, Gislason G, Skov L, Egeberg A. The association with cardiovascular disease and type 2 diabetes in adults with atopic dermatitis: a systematic review and meta‐analysis. Br J Dermatol. 2018;178(6):1272‐1279. doi:10.1111/bjd.16215
Silverwood RJ, Forbes HJ, Abuabara K, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ. 2018;361:k1786. doi:10.1136/bmj.k1786
Park JH, Jeong DY, Peyrin‐Biroulet L, Eisenhut M, Shin JI. Insight into the role of TSLP in inflammatory bowel diseases. Autoimmun Rev. 2017;16(1):55‐63. doi:10.1016/j.autrev.2016.09.014
Nemmer JM, Kuchner M, Datsi A, et al. Interleukin‐31 signaling bridges the gap between immune cells, the nervous system and epithelial tissues. Front Med. 2021;8:639097. doi:10.3389/fmed.2021.639097
Anzelc M, Burkhart CG. Pain and pruritus: a study of their similarities and differences. Int J Dermatol. 2020;59(2):159‐164. doi:10.1111/ijd.14678
Chiu IM, Heesters BA, Ghasemlou N, et al. Bacteria activate sensory neurons that modulate pain and inflammation. Nature. 2013;501(7465):52‐57. doi:10.1038/nature12479
Mohr N, Augustin M, Zeervi L, et al. Determinants of costs and benefits in atopic dermatitis routine care in Germany. J Eur Acad Dermatol Venereol. 2022;36(9):1450‐1455. doi:10.1111/jdv.18169
Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema: part I–systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409‐1431. doi:10.1111/jdv.18345
Bieber T, Paller AS, Kabashima K, et al. Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. J Eur Acad Dermatol Venereol. 2022;36(9):1432‐1449. doi:10.1111/jdv.18225
Wollenberg A, Kinberger M, Arents B, et al. First update of the living European guideline (EuroGuiDerm) on atopic eczema. J Eur Acad Dermatol Venereol. 2023;37(11):e1283‐e1287. doi:10.1111/jdv.19269
Silverberg JI, Guttman‐Yassky E, Thaçi D, et al. Two phase 3 trials of lebrikizumab for moderate‐to‐severe atopic dermatitis. N Engl J Med. 2023;388(12):1080‐1091. doi:10.1056/NEJMoa2206714
Drucker AM, Morra DE, Prieto‐Merino D, et al. Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta‐analysis. JAMA Dermatol. 2022;158(5):523‐532. doi:10.1001/jamadermatol.2022.0455
Davis DMR, Drucker AM, Alikhan A, et al. American Academy of Dermatology guidelines: awareness of comorbidities associated with atopic dermatitis in adults. J Am Acad Dermatol. 2022;86(6):1335‐1336.e18. doi:10.1016/j.jaad.2022.01.009
Akdis CA, Akdis M, Boyd SD, Sampath V, Galli SJ, Nadeau KC. Allergy: mechanistic insights into new methods of prevention and therapy. Sci Transl Med. 2023;15(679):eadd2563. doi:10.1126/scitranslmed.add2563
De Bruin‐Weller M, Biedermann T, Bissonnette R, et al. Treat‐to‐target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies. Acta Derm Venereol. 2021;101(2):adv00402. doi:10.2340/00015555-3751
Williams HC, Schmitt J, Thomas KS, et al. The HOME core outcome set for clinical trials of atopic dermatitis. J Allergy Clin Immunol. 2022;149(6):1899‐1911. doi:10.1016/j.jaci.2022.03.017
Ständer S. Atopic dermatitis. N Engl J Med. 2021;384(12):1136‐1143. doi:10.1056/NEJMra2023911
Weidinger S, Beck LA, Bieber T, Kabashima K, Irvine AD. Atopic dermatitis. Nat Rev Dis Primers. 2018;4(1):1. doi:10.1038/s41572-018-0001-z
Czarnowicki T, He H, Krueger JG, Guttman‐Yassky E. Atopic dermatitis endotypes and implications for targeted therapeutics. J Allergy Clin Immunol. 2019;143(1):1‐11. doi:10.1016/j.jaci.2018.10.032
Brunner PM, He H, Pavel AB, et al. The blood proteomic signature of early‐onset pediatric atopic dermatitis shows systemic inflammation and is distinct from adult long‐standing disease. J Am Acad Dermatol. 2019;81(2):510‐519. doi:10.1016/j.jaad.2019.04.036
Maintz L, Welchowski T, Herrmann N, et al. IL‐13, periostin and dipeptidyl‐peptidase‐4 reveal endotype‐phenotype associations in atopic dermatitis. Allergy. 2023;17. doi:10.1111/all.15647
Renert‐Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis‐a review on behalf of the international eczema council. J Allergy Clin Immunol. 2021;147(4):1174‐1190.e1. doi:10.1016/j.jaci.2021.01.013
Wollenberg A, Howell MD, Guttman‐Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti‐IL‐13 mAb. J Allergy Clin Immunol. 2019;143(1):135‐141. doi:10.1016/j.jaci.2018.05.029
Ungar B, Garcet S, Gonzalez J, et al. An integrated model of atopic dermatitis biomarkers highlights the systemic nature of the disease. J Invest Dermatol. 2017;137(3):603‐613. doi:10.1016/j.jid.2016.09.037
Khattri S, Shemer A, Rozenblit M, et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol. 2014;133(6):1626‐1634. doi:10.1016/j.jaci.2014.03.003
Bakker DS, Ariens LFM, Giovannone B, et al. EASI p‐EASI: predicting disease severity in atopic dermatitis patients treated with dupilumab using a combination of serum biomarkers. Allergy. 2020;75(12):3287‐3289. doi:10.1111/all.14492
Olydam JI, de Wijs LEM, Dik WA, Røpke MA, Da Rosa JC, Hijnen DJ. EASI p‐EASI: predicting disease severity in patients with atopic dermatitis treated with tralokinumab. J Invest Dermatol. 2022;142(12):3335‐3337.e1. doi:10.1016/j.jid.2022.06.008
Thijs JL, Drylewicz J, Bruijnzeel‐Koomen CAFM, et al. EASI p‐EASI: predicting disease severity in atopic dermatitis patients treated with cyclosporin A. Allergy. 2019;74(3):613‐617. doi:10.1111/all.13651
Wollenberg A, Kinberger M, Arents B, et al. European guideline (EuroGuiDerm) on atopic eczema–part II: non‐systemic treatments and treatment recommendations for special AE patient populations. J Eur Acad Dermatol Venereol. 2022;36(11):1904‐1926. doi:10.1111/jdv.18429
Akinlade B, Guttman‐Yassky E, de Bruin‐Weller M, et al. Conjunctivitis in dupilumab clinical trials. Br J Dermatol. 2019;181(3):459‐473. doi:10.1111/bjd.17869
Halling AS, Loft N, Silverberg JI, Guttman‐Yassky E, Thyssen JP. Real‐world evidence of dupilumab efficacy and risk of adverse events: a systematic review and meta‐analysis. J Am Acad Dermatol. 2021;84(1):139‐147. doi:10.1016/j.jaad.2020.08.051
Lang CCV, Renert‐Yuval Y, Del Duca E, et al. Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patients. Ann Allergy Asthma Immunol. 2021;127(3):334‐341. doi:10.1016/j.anai.2021.04.023
Brunner PM, Guttman‐Yassky E. Racial differences in atopic dermatitis. Ann Allergy Asthma Immunol. 2019;122(5):449‐455. doi:10.1016/j.anai.2018.11.015
Thyssen JP, Vestergaard C, Deleuran M, et al. European task force on atopic dermatitis (ETFAD): treatment targets and treatable traits in atopic dermatitis. J Eur Acad Dermatol Venereol. 2020;34(12):e839‐e842. doi:10.1111/jdv.16716
Bieber T. In search of the holy grail in atopic dermatitis: will dupilumab become the first disease‐modifying atopic dermatitis drug? J Allergy Clin Immunol. 2023;151(3):694‐696. doi:10.1016/j.jaci.2022.12.824
Thyssen JP, Schmid‐Grendelmeier P. Long‐term disease control in atopic dermatitis using biologics. Lancet. 2023;401(10372):172‐173. doi:10.1016/S0140-6736(22)02347-9
Schmid‐Grendelmeier P, Rapelanoro Rabenja F, Beshah AM, et al. How to integrate atopic dermatitis in the management of skin neglected tropical diseases in sub‐Saharan Africa? J Eur Acad Dermatol Venereol. 2023;37:e1040‐e1042. doi:10.1111/jdv.19096
Herrmann A, Lenzer B, Müller BS, et al. Integrating planetary health into clinical guidelines to sustainably transform health care. Lancet Planet Health. 2022;6(3):e184‐e185. doi:10.1016/S2542-5196(22)00041-9
The International Eczema Council, The International Society for Atopic Dermatitis, The European Taskforce for Atopic Dermatitis, The International League of Dermatological Societies, The International Alliance of Dermatology Patient Organizations (Global Skin). The Global Atopic Dermatitis Atlas. Accessed December 18, 2023. https://www.eczemacouncil.org/global‐atopic‐dermatitis‐atlas
Heratizadeh A, Werfel T, Wollenberg A, et al. Effects of structured patient education in adults with atopic dermatitis: multicenter randomized controlled trial. J Allergy Clin Immunol. 2017;140(3):845‐853.e3. doi:10.1016/j.jaci.2017.01.029
Traidl S, Lang C, Schmid‐Grendelmeier P, Werfel T, Heratizadeh A. Comprehensive approach: current status on patient education in atopic dermatitis and other allergic diseases. Handb Exp Pharmacol. 2022;268:487‐500. doi:10.1007/164_2021_488
Gerth van Wijk R, Mülleneisen N, Demoly P, et al. The roadmap for allergology in Europe: the European training requirements for the specialty of allergology. Allergy. 2021;76(5):1588‐1591. doi:10.1111/all.14614
Goi HC, Tan WL. Design thinking as a means of citizen science for social innovation. Front Sociol. 2021;6:629808. doi:10.3389/fsoc.2021.629808
Straub Piccirillo D, Schmid‐Grendelmeier P, Hitzler M, Lauener R. Continuing medical education activities for improved management of allergy patients. Allergy. 2018;73(6):1351‐1353. doi:10.1111/all.13443
Guest C, Wainwright P, Herbert M, Smith IM. Driving quality improvement with a massive open online course (MOOC). BMJ Open Qual. 2021;10(1):e000781. doi:10.1136/bmjoq-2019-000781
Nieder J, Nayna Schwerdtle P, Sauerborn R, Barteit S. Massive open online courses for health worker education in low‐ and middle‐income countries: a scoping review. Front Public Health. 2022;10:891987. doi:10.3389/fpubh.2022.891987
Gudmundsdóttir SL, Ballarini T, Ámundadóttir ML, et al. Engagement, retention, and acceptability in a digital health program for atopic dermatitis: prospective interventional study. JMIR Form Res. 2023;7:e41227. doi:10.2196/41227
Kiani C, Steiner C, Zink A. Smart skin‐a new technology in the area of digital dermatology. Dermatologie (Heidelb). 2022;73(11):891‐900. doi:10.1007/s00105-022-05066-6